SUNZEN BIOTECH BHD
KLSE (MYR): SUNZEN (0148)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
0.315
Today's Change
-0.005 (1.56%)
Day's Change
0.31 - 0.32
Trading Volume
126,100
Financial
Market Cap
Market Cap
254 Million
NOSH
805 Million
Latest Quarter
Latest Quarter
30-Sep-2024 [#1]
Announcement Date
22-Nov-2024
Next Quarter
31-Dec-2024
Est. Ann. Date
28-Feb-2025
Est. Ann. Due Date
01-Mar-2025
QoQ | YoY
19.60% | -71.53%
T4Q Result
Revenue | NP to SH
96,871.000 | 5,966.000
RPS | P/RPS
12.03 Cent | 2.62
EPS | P/E | EY
0.74 Cent | 42.51 | 2.35%
DPS | DY | Payout %
0.00 Cent | 0.00% | 0.00%
NAPS | P/NAPS
0.18 | 1.79
QoQ | YoY
-16.87% | 23.55%
NP Margin | ROE
6.50% | 4.21%
F.Y. | Ann. Date
30-Sep-2024 | 22-Nov-2024
Latest Audited Result
Latest Audited Result
30-Jun-2024
Announcement Date
30-Oct-2024
Next Audited Result
30-Jun-2025
Est. Ann. Date
30-Oct-2025
Est. Ann. Due Date
27-Dec-2025
Annual (Unaudited)
Revenue | NP to SH
142,699.000 | 9,172.000
RPS | P/RPS
17.72 Cent | 1.78
EPS | P/E | EY
1.14 Cent | 27.65 | 3.62%
DPS | DY | Payout %
0.00 Cent | 0.00% | 0.00%
NAPS | P/NAPS
0.18 | 1.80
YoY
null%
NP Margin | ROE
7.31% | 6.50%
F.Y. | Ann. Date
30-Jun-2024 | 29-Aug-2024
Annualized Result
Revenue | NP to SH
91,856.000 | 1,928.000
RPS | P/RPS
11.41 Cent | 2.76
EPS | P/E | EY
0.24 Cent | 131.55 | 0.76%
DPS | DY | Payout %
-
NAPS | P/NAPS
-
QoQ | YoY
-78.98% | -60.79%
NP Margin | ROE
1.09% | 1.36%
F.Y. | Ann. Date
30-Sep-2024 | 22-Nov-2024
Business Process
| Trailing 4 Quarters | Trailing 8 Quarters | |||
|---|---|---|---|---|
| Available Quarters | 4 Quarters | 8 Quarters | ||
| Continuous Quarters Of Revenue Growth | 1 / 4 | 25.00% | 1 / 8 | 12.50% |
| Total Positive Profit Years | 4 / 4 | 100.00% | 8 / 8 | 100.00% |
| Continuous Quarters Of Positive Profit | 4 / 4 | 100.00% | 8 / 8 | 100.00% |
| Continuous Quarters Of Profit Growth | 1 / 4 | 25.00% | 1 / 8 | 12.50% |
| Continuous Quarters Of Adjusted EPS Growth | 1 / 4 | 25.00% | 1 / 8 | 12.50% |
| Total Dividend Years | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Continuous Quarters Of Dividend | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Continuous Quarters Of Dividend Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Continuous Quarters Of Adjusted Dps Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Average ROE | 1.14% | 1.06% | ||
| Average Net Profit Margin | 5.94% | 6.18% | ||
| Last 5 Financial Years | Last 10 Financial Years | |||
|---|---|---|---|---|
| Available Years | 5 Years | 10 Years | ||
| Continuous Quarters Of Revenue Growth | 1 / 5 | 20.00% | 1 / 10 | 10.00% |
| Total Positive Profit Years | 3 / 5 | 60.00% | 4 / 10 | 40.00% |
| Continuous Quarters Of Positive Profit | 1 / 5 | 20.00% | 1 / 10 | 10.00% |
| Continuous Quarters Of Profit Growth | 1 / 5 | 20.00% | 1 / 10 | 10.00% |
| Continuous Quarters Of Adjusted EPS Growth | 1 / 5 | 20.00% | 1 / 10 | 10.00% |
| Total Dividend Years | 0 / 5 | 0.00% | 1 / 10 | 10.00% |
| Continuous Quarters Of Dividend | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Continuous Quarters Of Dividend Growth | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Continuous Quarters Of Adjusted Dps Growth | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Average ROE | -0.90% | -2.81% | ||
| Average Net Profit Margin | -0.29% | -1.18% | ||
Key Result
| T4Q | Annualized | Annual (Unaudited) | Last 10 FY Average | Last 5 FY Average | |
|---|---|---|---|---|---|
| Revenue | 96,871 | 91,856 | 142,699 | 132,845 | 82,495 |
| NP to SH | 5,966 | 1,928 | 9,172 | -2,105 | 55 |
| Dividend | 0 | 0 | 0 | 144 | 0 |
| Adjusted EPS | 0.74 | 0.24 | 1.14 | -0.26 | 0.01 |
| Adjusted DPS | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 |
NP to SH = Net Profit Attributable to Shareholder, EPS = Earning Per Share, DPS = Dividend Per Share
All figures in '000 unless specified.
EPS & DPS's figures in Cent.
Growth
| LQ QoQ | LQ YoY | CQ YoY | LQ vs Average of T4Q | LQ vs Average of T8Q | |
|---|---|---|---|---|---|
| Revenue | 11.42% | -11.62% | -66.62% | -5.18% | 0.55% |
| NP to Owner | 19.60% | -71.53% | -86.93% | -67.68% | -64.28% |
| Dividend | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Adjusted EPS | 19.60% | -71.53% | -86.93% | -67.68% | -64.28% |
| Adjusted DPS | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
LQ = Latest Quarter, CQ = Cumulative Quarter, T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, QoQ = Quarter on Quarter, YoY = Year on Year
| T4Q vs LFY | T4Q vs AL5FY | T4Q vs AL10FY | AQR vs LFY | AQR vs AL5FY | AQR vs AL10FY | LFY YoY | LFY vs AL5FY | LFY vs AL10FY | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | -32.12% | 17.43% | -27.08% | -35.63% | 11.35% | -30.86% | 0.00% | 72.98% | 7.42% |
| NP to Owner | -34.95% | 10,747.27% | 383.30% | -78.98% | 3,405.45% | 191.55% | 0.00% | 16,576.36% | 535.54% |
| Dividend | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Adjusted EPS | -34.95% | 10,747.25% | 383.30% | -78.98% | 3,405.45% | 191.55% | 0.00% | 16,576.33% | 535.54% |
| Adjusted DPS | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, AL5FY = Average of Last 5 Financial Years, AL10FY = Average of Last 10 Financial Years, LFY = Latest Financial Year AQR = Annualized Quarter Result, YoY = Year on Year
Discussions
5 people like this. Showing 50 of 2,230 comments
Strong growth every quarter, Sunzen future prospect is really bright with new acquisition
2024-08-09 16:10
Next quarter's revenue and net profit will both increase quarter-on-quarter and year-on-year, I believe
2024-08-12 20:08
Sunzen has decreased current liabilities to 6.3% of total assets over this period. Good sign
2024-08-13 16:15
I just watched it. Must say the new management seems to be doing the right thing compare to the previous one. At least now SUNZEN is no longer losing money but making profit
2024-09-23 10:20
Hopes the Xmegami lenglui will buy in sunzen also since their earning so high every month
2 months ago
Watched the technical analysis here https://youtu.be/9V0_mkxG1sw?si=M-l0iuIJeU4w9q5Q
2 months ago
Dow Jones
Dow Jones Industrial Average
42,011.59
-184.93
0.43%
Nasdaq
NASDAQ Composite
17,918.47
-6.64
0.03%
2 months ago
Share price still steady after that, biggie0000. We wait for the next rally to come
1 month ago
As consumers pay more and more attention to preventive health care and natural remedies, Sunzen's traditional Chinese medicine and human health supplement products have huge growth potential
1 month ago
Nice grab, gloveshapiro. If the QR is good as expected, it probably will break 35 cents
1 month ago
Sunzen Biotech eyes bigger share of China bird’s nest market. Sunzen subsidiary Ecolite Biotech Manufacturing Sdn Bhd has received approval from China’s customs authority in October last year to export its bottled bird’s nest to the country up to 2028.
1 month ago
The demand for edible bird’s nest products is indeed strong in China, Hong Kong, and other parts of Southeast Asia. The Chinese market, in particular, is one of the largest consumers of bird’s nests, driven by a cultural preference for traditional health products and rising disposable incomes
1 month ago
Sunzen's loan financing business is expected to continue to grow given the increasing trend in the number of applications and approvals, mainly due to our ability to provide fast and efficient services and structure more flexible loan packages to meet the needs of the SME market.
1 month ago
Acquisition of Eye Nation Medical is expected to contribute positively to the future financial performance of the Sunzen group, enhancing the group’s revenue and profitability, as it is secured by a profit guarantee of an audited profit after tax of RM2.60 million over the next two financial years
1 month ago
Then SUNZEN will be able to achieve over RM1 million of net profit in the next quarter 😀
1 month ago
more expansion into the healthcare sector, Sunzen keep building & growing... TP 0.40
1 month ago
QR was out, the company reported revenue of RM22.96 million and PBT of RM0.86 million. In the current quarter, human health products and loan financing accounted for 76.85% and 14.26%, respectively, while the remaining 8.89% came from the animal health business.
3 weeks ago
why so sour, eye nation & ecolite biotech will start bringin in more profit next quarter
3 weeks ago
Malaysia is one of the world’s largest producers of bird’s nest, with a significant portion of its production exported to China, where demand remains robust. Maintain a "buy" rating on Sunzen
2 weeks ago
SUNZEN GROUP BERHAD SEES SHAREHOLDERS SUPPORT IN AGM WITH APPROVAL IN ALL 9 RESOLUTIONS
2 days ago
Post a Comment
Featured Posts
Latest Videos
Apps
Top Articles
1
Stock Market Enthusiast
Top 3 AI/Data Center Newsflow for the 3rd Week of December - #TENAGA, #YTL, #YTLPOWER
2
Rakuten Trade Research Reports
3
save malaysia!
4
Good Articles to Share
5
Good Articles to Share
6
Good Articles to Share
Gaza ceasefire deal 'closer than ever', says Hamas and two allies
7
Good Articles to Share
Ryan Serhant makes bold pitch to fix the housing ‘affordability crisis’
8
Good Articles to Share
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
gloveshapiro
0.31-0.32 is a steady & cheap entry price now, Sunzen entering the healthcare sector will push the price further up
2024-08-08 15:07